IMUX
OVID

Jason Tardio

Known title: Chief Operating OfficerCIK: 0001794698

Jason Tardio's purchase track record

Jason Tardio has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
6/5/2025IMUX$10K-0.4%-11.0%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 7, 2026

Immunic Presents Four Abstracts at MSToronto2026. Immunic announced that four of its research abstracts were accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting, known as MSToronto2026. This event highlights the company's ongoing scientific activity in its field. The stock is currently trading near its 52-week low, with an RSI of 22.5 indicating oversold conditions.

this person other insiders at IMUX

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 29, 2026

Ovid Therapeutics shares decline in pre-market session. Ovid Therapeutics stock fell during Tuesday's pre-market trading, joining a group of larger companies experiencing similar declines. The drop brings the stock closer to its recent support level of $2.38. This movement occurs while the average analyst price target remains significantly higher at $5.92.

this person other insiders at OVID

Transaction History

IMUX▲ Buy$10K
OVID▲ Buy$0
OVID▼ Sell$37K

We use analytics to understand how market-wall is used. No personal data is sold.